AGM/EGM Notice
Fischer Medical Ventures Postal Ballot Results
Fischer Medical Ventures reported that postal ballot resolutions 1, 3, 6 and 7 were approved, while resolutions 2, 4 and 5 concerning related-party transactions were not passed.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY25
Investor Presentation
Q2 FY25
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Bearish
3
Neutral
2
Bullish
9
Bearish
35
Neutral
2
Bullish
9
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Healthcare Equipment & Supplies
Medical Equipment & Supplies
1,635 Cr
Low Risk
97.8
60.1
0.1
3.5
50.34
21.94
Sales CAGR
Profit CAGR
ROE
ROCE

Fischer Medical Ventures Ltd (FISCHER) is currently trading at 23.31 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Fischer Medical Ventures Limited builds, manufactures and commercialises medical imaging systems and an AI-driven healthcare platform, combining MRI, CT, X‑ray and mammography hardware with MIDAS, ATLAS and LIVE Dx software for screening, diagnostics and hospital digitization across India and international markets. The company claims vertical IP across magnets, RF coils, gradients, consoles and AI, positioning itself as a full-stack imaging vendor that can deliver helium-free, energy-efficient MRI systems from 0.35T open-bore units up to research 7T platforms and mobile screening solutions. FMV emphasises population-scale screening: MIDAS and LIVE Dx convert episodic diagnostics into continuous surveillance with multi-organ AI modules, mobile MRI and portable X‑ray workflows — a distinct strategic bet on preventive care, corporate screening and public-health programmes. The group has a diversified portfolio of portfolio companies — NanoMedic (portable wound electrospinning), Obelab (fNIRS), Nervotec (contactless vitals) and Nanyang Biologics (AI drug discovery) — creating cross-selling and clinical validation opportunities across devices, software and therapeutics.
Over the past 52 weeks, Fischer Medical Ventures Ltd has traded between a low of ₹21.94 and a high of ₹50.34. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Fischer Medical Ventures Ltd has a market capitalization of approximately 1,634.92. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Fischer Medical Ventures Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 97.84 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,634.92 Cr, Fischer Medical Ventures Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Fischer Medical Ventures Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Fischer Medical Ventures Ltd is 97.84. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Fischer Medical Ventures reported Rs 77.5184 crore of proceeds from equity shares issued on warrant conversion in the half year ended September 30, 2026. The five August allotment disclosures list balance exercise payments totalling Rs 77.51834998 crore, with the small difference reflecting rounding in the cash-flow presentation.
Fischer Medical Ventures reported standalone profit after tax of Rs 20.58 crore for the quarter ended September 30, 2026. This compared with Rs 83.77 lakh in the quarter ended September 30, 2025 and a loss of Rs 3.50 crore in the quarter ended June 30, 2026.
Infomerics reported no deviation in Fischer Medical Ventures' use of ₹358.45 crore raised through its preferential issue for the quarter ended September 30, 2026. The report said ₹332.56 crore had been utilised by that date.
Shankar Varadharajan and PACs increased their aggregate shareholding to 62.66% of the total voting capital after the August 12, 2026 transaction.
AGM/EGM Notice
Fischer Medical Ventures reported that postal ballot resolutions 1, 3, 6 and 7 were approved, while resolutions 2, 4 and 5 concerning related-party transactions were not passed.
Financial Results
Fischer Medical Ventures approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, at its November 14, 2026 board meeting.
Regulatory/Compliance Filing
Fischer Medical Ventures submitted the Monitoring Agency Report for the quarter ended September 30, 2026, covering utilisation of proceeds from its preferential issue.
Board Meeting
Fischer Medical Ventures will consider unaudited standalone and consolidated results for Q2 and the half year ended September 30, 2026, at its November 14 board meeting.